The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications
E Campo, SH Swerdlow, NL Harris… - Blood, The Journal …, 2011 - ashpublications.org
Abstract The World Health Organization classification of lymphoid neoplasms updated in
2008 represents a worldwide consensus on the diagnosis of these tumors and is based on …
2008 represents a worldwide consensus on the diagnosis of these tumors and is based on …
Diffuse large B-cell lymphoma
Diffuse large B cell lymphoma (DLBCL) is the most common type of non-Hodgkin lymphoma
worldwide, representing approximately 30–40% of all cases in different geographic regions …
worldwide, representing approximately 30–40% of all cases in different geographic regions …
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
H Tilly, MG Da Silva, U Vitolo, A Jack… - Annals of …, 2015 - annalsofoncology.org
Diffuse large B-cell lymphoma (DLBCL) constitutes 30%–58% of non-Hodgkin's lymphoma
series. The crude incidence in Europe is 3.8/100 000/year [1]. The incidence increases with …
series. The crude incidence in Europe is 3.8/100 000/year [1]. The incidence increases with …
Concurrent expression of MYC and BCL2 in diffuse large B-cell lymphoma treated with rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone
Purpose Diffuse large B-cell lymphoma (DLBCL) is curable in 60% of patients treated with
rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC …
rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP). MYC …
MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene …
Diffuse large B-cell lymphoma (DLBCL) is stratified into prognostically favorable germinal
center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on …
center B-cell (GCB)–like and unfavorable activated B-cell (ABC)–like subtypes based on …
Determining cell-of-origin subtypes of diffuse large B-cell lymphoma using gene expression in formalin-fixed paraffin-embedded tissue
DW Scott, GW Wright, PM Williams… - Blood, The Journal …, 2014 - ashpublications.org
The assignment of diffuse large B-cell lymphoma into cell-of-origin (COO) groups is
becoming increasingly important with the emergence of novel therapies that have selective …
becoming increasingly important with the emergence of novel therapies that have selective …
Prognostic significance of diffuse large B-cell lymphoma cell of origin determined by digital gene expression in formalin-fixed paraffin-embedded tissue biopsies
DW Scott, A Mottok, D Ennishi, GW Wright… - Journal of clinical …, 2015 - ascopubs.org
Purpose To evaluate the prognostic impact of cell-of-origin (COO) subgroups, assigned
using the recently described gene expression–based Lymph2Cx assay in comparison with …
using the recently described gene expression–based Lymph2Cx assay in comparison with …
Rearrangement of MYC Is Associated With Poor Prognosis in Patients With Diffuse Large B-Cell Lymphoma Treated in the Era of Rituximab
S Barrans, S Crouch, A Smith, K Turner… - Journal of clinical …, 2010 - ascopubs.org
Purpose Rearrangement of MYC occurs in a proportion of diffuse large B-cell lymphomas
(DLBCL), where they may be associated with an adverse clinical outcome. The aim of this …
(DLBCL), where they may be associated with an adverse clinical outcome. The aim of this …
Diffuse large B-cell lymphoma
M Martelli, AJM Ferreri, C Agostinelli, A Di Rocco… - Critical reviews in …, 2013 - Elsevier
Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoid malignancy in adults
accounting for 31% of all NHL in Western Countries. Following, morphological, biological …
accounting for 31% of all NHL in Western Countries. Following, morphological, biological …
Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab
PN Meyer, K Fu, TC Greiner, LM Smith… - Journal of clinical …, 2011 - ascopubs.org
Purpose Patients with diffuse large B-cell lymphoma (DLBCL) can be divided into prognostic
groups based on the cell of origin of the tumor as determined by microarray analysis …
groups based on the cell of origin of the tumor as determined by microarray analysis …